| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue ( from related party for the three months ended xxx, respectively) | 2,397 | 3,941 | 2,198 | 2,667 |
| Research and development | 20,611 | 23,815 | 22,401 | 27,692 |
| General and administrative | 8,066 | 8,579 | 9,197 | 10,403 |
| Impairment charges | NaN | 0 | 0 | 12,150 |
| Total operating expenses | 28,677 | 32,394 | 31,598 | 50,245 |
| Loss from operations | -26,280 | -28,453 | -29,400 | -47,578 |
| Impairment of equity method investment | NaN | -785 | 0 | -9,158 |
| Change in fair value of the mskcc success payments liability | NaN | NaN | 0 | -451 |
| Other income, net | 1,195 | 2,200 | 1,852 | 2,187 |
| Total other income | 1,195 | 1,415 | 1,852 | -6,520 |
| Net loss before benefit from income taxes | NaN | -26,625* | NaN | NaN |
| Benefit from income taxes | NaN | -137* | NaN | NaN |
| Net loss | -25,085 | -26,488 | -27,548 | -54,098 |
| Net unrealized gain on available-for-sale marketable securities, net of tax | -126 | 10 | 53 | -127 |
| Net comprehensive loss | -25,211 | -26,478 | -27,495 | -54,225 |
| Basic EPS | -0.26 | -0.28 | -0.3 | -0.58 |
| Diluted EPS | -0.26 | -0.28 | -0.3 | -0.58 |
| Basic Average Shares | 95,861,716 | 94,555,842 | 93,293,099 | 93,028,698 |
| Diluted Average Shares | 95,861,716 | 94,555,842 | 93,293,099 | 93,028,698 |
Caribou Biosciences, Inc. (CRBU)
Caribou Biosciences, Inc. (CRBU)